Monitoring Parameters for Norethindrone and Estradiol Therapy

Baseline Assessment and Ongoing Monitoring

The American Academy of Dermatology recommends monitoring blood pressure at baseline and regularly during treatment, as combined estrogen-progestin therapy increases cardiovascular and thromboembolic risk, particularly in women with pre-existing risk factors 1, 2
Pregnancy status must be confirmed negative before initiating therapy, as this combination is pregnancy category X 1, 2
The American Academy of Dermatology suggests screening for absolute contraindications, including active or history of thromboembolic disease, uncontrolled hypertension, hepatic disease, breast cancer, and migraine headaches with focal neurologic symptoms 1, 2, 3

Blood pressure checks are necessary at every visit, as hypertension is a common adverse effect and increases stroke risk 1, 2
Monitoring for signs of hepatotoxicity, including jaundice, right upper quadrant pain, or abnormal liver function, is crucial 1, 2

Assessing bleeding patterns at each visit is important, as breakthrough bleeding, amenorrhea, and irregular menstruation are common 1, 2
Screening for new-onset or worsening headaches, particularly migraines with aura, is necessary, as they require immediate discontinuation 1, 2

Women ≥35 years have substantially increased stroke risk, particularly if they smoke or have other cardiovascular risk factors 6, 3
The risk of stroke increases after 1 year of use and continues to rise with each additional 5 years of therapy 6
The estrogen dose-response relationship shows increased stroke risk of OR 1.19 per 10 μg estrogen 6

Reviewing all medications at each visit is necessary, as norethindrone/estradiol interacts with numerous drugs that can either reduce contraceptive efficacy or increase toxicity 1, 4, 5
The American Academy of Dermatology recommends monitoring for interactions with antibiotics, anticonvulsants, HIV protease inhibitors, and St. John's wort 1, 4, 5